Expanding the ICAM-1 space

Candidates targeting intercellular adhesion molecule-1 for inflammatory disease have been in development for more than a decade. Now BioInvent International AB is building a case for the role of ICAM-1 in multiple myeloma.

The biotech recently started a Phase I trial of its BI-505 in the cancer. The humanized mAb was discovered using the company's BioPanning drug discovery process...